OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers Jun 27, 2019 8:30am EDT
OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator Jun 17, 2019 8:30am EDT
OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility May 28, 2019 8:30am EDT
UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer May 23, 2019 8:30am EDT
OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer May 22, 2019 8:30am EDT
OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries May 21, 2019 8:30am EDT
